Potential of plasmid only based reverse genetics of rotavirus for the development of next-generation vaccines

Abstract

Plasmid only based reverse genetics (RG) systems for species A rotaviruses (RVA) are available since 2017 and are beginning to be explored in structure-function and viral replication studies as well as for testing of antivirals. The rescue of human rotavirus genomes into viable particles, the expression of heterologous genes from fusion constructs with rotavirus genes, and the possibility to obtain safely attenuated recombinant rotaviruses are of great promise for the production of next-generation rotavirus vaccine candidates. In the context attention is drawn to issues, which arose during the development of reverse genetics-created recombinant influenza virus vaccine candidates.